February 16, 2010
NEW YORK (Dow Jones)--Biogen Idec Inc. (BIIB) disclosed four more cases of a rare brain infection in multiple sclerosis patients on Tysabri, which it sells with Elan Corp. (ELN), bringing the total number of cases to 35.
The number of deaths stands at eight with patients that have developed progressive multifocal leukoencephalopathy, or PML, according to the Cambridge, Mass., biotech company.
To read the full story, click here.